Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Sellas Life Sciences stock soars as much as 233% after cancer vaccine cut death risk in trial

Company plans to meet with the FDA and is preparing a biologics license application for the first half of 2027

Sellas Life Sciences stock soars as much as 233% after cancer vaccine cut death risk in trial

We haven't written up this one. Quartz has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Every outlet that reported this, and when →

Read the original at qz.com →

More in Finance & Markets

More from Tuesday 17 November →